English | Español

Institute for Clinical and Economic Review
+ Regulatory
John Breslin | May 17, 2018

Cystic fibrosis sufferers, families and physicians push back at medication value study

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'